NICE reverses Alunbrig stance
The National Institute for Health and Care Excellence (NICE) has recommended Alunbrig (brigatinib) being provided on the National Health Service (NHS) in England for anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults who have already had Xalkori (crizotinib).
This guidance within a final appraisal document (FAD) follows negotiations involving the drug company Takeda (TYO: 4502), the NICE, NHS England, and the clinical and patient community to reverse the draft negative recommendation published in October 2018.
The first ALK inhibitor to be available, Pfizer’s (NYSE: PFE) Xalkori (crizotinib), has had a significant impact on the outcome of ALK-positive NSCLC patients over recent years, with the majority of patients that received it in clinical trials progressing within a year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze